Clinical trials: Idiopathic Inflammatory Myositis
Fibrodysplasia Ossificans Progressiva
A Study to Assess the Effectiveness and Safety of 2 Dosage Regimens of Oral Fidrisertib (IPN60130) for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP).
Fibrodysplasia Ossificans Progressiva (FOP) is a rare, severely disabling disease characterized by the presence of bone in soft tissue where bone normally does not exist, known as Heterotopic Ossification (HO).
- Trial name
- FALKON (NCT05039515)
- Testing
- IPN60130
- Where
- 25 sites in United States, Argentina and 12 more
- Volunteers
- 113 people
- Sponsor
- Clementia Pharmaceuticals Inc.
Sporadic Inclusion Body Myositis (sIBM), Idiopathic Inflammatory Myopathies
Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients With Sporadic Inclusion Body Myositis
To evaluate the efficacy of Pozelimab/Cemdisiran combination therapy in patients with sIBM
- Trial name
- NCT06479863
- Testing
- Pozelimab/Cemdisiran
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Austin Neuromuscular Center
Lupus, Dermatomyositis, Juvenile
Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress
The objectives of this study are to determine if the 'Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress' (TEAM-LEADS) intervention is feasible and acceptable to adolescents…
- Conditions
- Lupus, Dermatomyositis, Juvenile, Dermatomyositis, Lupus Erythematosus
- Trial name
- TEAM-LEADS (NCT06999109)
- Testing
- TEAM-LEADS
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Duke University
Fibrodysplasia Ossificans Progressiva
Study of Single-Ascending Doses of DS-6016a in Healthy Japanese Subjects
This study will assess the safety, tolerability, and pharmacokinetics of DS-6016a after subcutaneous injection in healthy Japanese participants.
- Trial name
- NCT04818398
- Testing
- DS-6016a
- Where
- Japan
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Daiichi Sankyo Co., Ltd.
Idiopathic Inflammatory Myopathies (IIMs)
Clinical Characteristics and Mechanism Research of Deucravacitinib in the Idiopathic Inflammatory Myopathies
This study aims to explore the clinical characteristics and mechanism of Deucravacitinib in the treatment of idiopathic inflammatory myopathies.Detailed Description: The investigators designed a single center, open-label…
- Trial name
- NCT07564271
- Testing
- Deucravacitinib 6mg po qd
- Where
- China
- Sponsor
- Peking University People's Hospital
Dermatomyositis, Inclusion Body Myositis
Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies
Inflammatory myopathies are a group of muscle diseases characterized by muscle weakness, high levels of muscle enzymes in the blood, and inflammation of the tissue surrounding muscle fibers (endomysium).
- Conditions
- Dermatomyositis, Inclusion Body Myositis, Polymyositis
- Trial name
- NCT00001261
- Testing
- Gamma Globulin
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Myositis
Multispectral Optoacustic Imaging in Patients With Myositis
Myositis syndromes are a relatively rare group of diseases in which acquired inflammation of the muscles occurs. According to clinical, histological and immunopathological criteria, autoimmune (dermatomyositis, polymyositis…
- Trial name
- MYOMSOT (NCT06966739)
- Testing
- MSOT of musculature
- Where
- Germany
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- University of Giessen
IBM, Inclusion Body Myositis
Establishing Muscle Impedance Parameters With Electrical Impedance Myography
The primary aim of this study is to assess the changes in the impedance parameters of muscles in inclusion body myositis (IBM) through electrical impedance myography (EIM), an emerging non-invasive electrodiagnostic technology.
- Trial name
- NCT03633318
- Testing
- electrical impedance myography (EIM)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Yale University
Myositis
Physical Exercise as a Targeted Therapy in Patients With Chronic Rheumatic Muscle Inflammation
The objectives of this study are to test if hypoxia in muscle tissue is an important factor contributing to clinical symptoms in chronic rheumatic muscle inflammation and to evaluate if a 12 week endurance exercise program will…
- Trial name
- NCT01184625
- Testing
- Physical Exercise
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Karolinska Institutet
Refractory Autoimmune Diseases
A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases
The purpose of this study is to determine the safety, tolerability, optimal dose, and preliminary efficacy of BMS-986515, a healthy donor (HD) allogeneic CD19-targeted CART cell product, in participants with severe, refractory…
- Trial name
- NCT07115745
- Testing
- BMS-986515, Fludarabine, Cyclophosphamide
- Where
- 28 sites in United States, Australia and 8 more
- Volunteers
- 125 people
- Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Dermatomyositis (DM), Juvenile Dermatomyositis (JDM)
FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)
Dermatomyositis (DM) is a rare autoimmune disease that causes muscle weakness, skin rashes, and other symptoms. Researchers think both genetic and environmental factors play a role in this disease.
- Trial name
- NCT07111065
- Testing
- FISH OIL 500MG OMEGA-3 SOFT GEL MINIS
- Where
- United States
- Volunteers
- 3,000 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Juvenile Dermatomyositis
Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis
This is a Phase I clinical trial to evaluate the efficacy and safety of CD19-targeted CAR-T in the treatment of refractory juvenile dermatomyositis (RJDM).The experiment was divided into two phases: dose exploration (Part A) and…
- Trial name
- NCT06569472
- Testing
- CD19-targetd CAR-T
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Vasculitis, Hypersensitivity, Connective Tissue Diseases
Absorption of Corticosteroids in Children With Juvenile Dermatomyositis
Juvenile dermatomyositis (JDM) is a connective tissue disease that causes skin rash and weak muscles in children. The purpose of this study is to measure the absorption of oral prednisolone and intravenous (IV) methylprednisolone…
- Conditions
- Vasculitis, Hypersensitivity, Connective Tissue Diseases, Dermatomyositis, Vasculitis
- Trial name
- NCT00004357
- Testing
- Methylprednisolone, Prednisolone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Northwestern University
Polymyositis, Dermatomyositis
Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
This study determined the efficacy, safety, tolerability and the PK profile of BAF312, a novel immunomodulator, in polymyositis and dermatomyositis patients who were not responsive to traditional immunosuppressive and/or…
- Trial name
- NCT01148810
- Testing
- BAF312
- Where
- 6 sites in United States, Czechia and 3 more
- Volunteers
- 18 people
- Sponsor
- Novartis Pharmaceuticals
Sporadic Inclusion Body Myositis (sIBM)
Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
This study is an open-label, long-term study for those patients who participated in the prior proof-of-concept protocol, in which the preliminary efficacy for BYM338 in patients with sIBM was demonstrated after a single 30 mg/kg…
- Trial name
- BYM338 (NCT02250443)
- Testing
- BYM338 (Bimagrumab)
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Novartis Pharmaceuticals
Juvenile Dermatomyositis
Incidence and Prevalence of Juvenile Dermatomyositis
This is a descriptive, retrospective, multi-center, cross-sectional and observational epidemiological study of incidence and prevalence of juvenile dermatomyositis in Alsace from 2000 to 2015.
- Trial name
- NCT03432455
- Where
- France
- Volunteers
- 22 people
- Sponsor
- University Hospital, Strasbourg, France
Systemic Sclerosis, Other Connective Tissue Disease
Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis
Systemic SClerosis (SSC) is a systemic disease characterized by limited or diffuse cutaneous sclerosis, microangiopathy, overproduction of autoantibodies and variable organ damage due to vasculopathy and/or fibrosis.
- Conditions
- Systemic Sclerosis, Other Connective Tissue Disease, Systemic Lupus Erythematosus, Dermatomyositis
- Trial name
- NETOSE (NCT06462768)
- Testing
- Blood sample
- Where
- France
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- CHU de Reims
Interstitial Lung Disease
Pulmonary Care and Research Collaborative Patient Registry
The purpose of this research study is to build and maintain a registry of people with interstitial lung disease (ILD). Medical information collected for this registry may be used to advance ILD and pulmonary research and improve…
- Trial name
- NCT05445817
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Pulmonary Care and Research Collaborative Limited
Osteoporosis, Juvenile Rheumatoid Arthritis
Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders
The purpose of this study is to evaluate denosumab as a novel treatment for bone loss in children treated with glucocorticoids for rheumatic disorders.
- Conditions
- Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis
- Trial name
- NCT02418273
- Testing
- denosumab
- Where
- United States
- Sponsor
- Indiana University
Refractory Myositis
Treatment With TNF Blockade, Infliximab, in Patients With Myositis
This is a 4 month open trial with TNF-blockade using infliximab (an antibody that blocks TNF) in adult patients with chronic myositis (polymyositis, dermatomyositis, inclusion body myositis) who have persisting muscle weakness…
- Trial name
- NCT00443222
- Testing
- Infliximab
- Sponsor
- Karolinska Institutet